About the group
Our group aims to develop new T-cell based concepts for cancer immunotherapy that overcome the major challenge of self-tolerance in cancer.
To this end, one of our main strategies involves studies of how the immune system from healthy donors can target patient cancer cells.
Our goals
We have a strong focus on the development of new technologies that allow high-throughput identification of therapeutic targets that can evoke immune responses, as lack of immunogenic targets represents a major limitation in therapeutic efficacy.
The group furthermore has a strong translational focus and performs penetrating mechanistic analyses in clinical trials together with our clinical partners.
